Raymond James Slashes PT on Axogen (AXGN) to $20 From $21

Axogen, Inc. (NASDAQ:AXGN) is one of the best medical device stocks to buy according to analysts. On August 6, Raymond James analyst Jayson Bedford lowered the firm’s price target on Axogen, Inc. (NASDAQ:AXGN) to $20 from $21, keeping an Outperform rating on the shares.

The analyst told investors in a research note that Axogen, Inc.’s (NASDAQ:AXGN) Q2 results exhibited a step-up in momentum, with gross margin and revenue growth both demonstrating an improvement.

He added that while the low end of H2 guidance points towards a growth deceleration, it appears to be conservative given recent trends and contribution from newly added reps.

Axogen, Inc. (NASDAQ:AXGN) develops and markets surgical solutions for peripheral nerve regeneration and repair. The company’s products include avive soft tissue membrane, acroval neurosensory and motor testing system, avance nerve graft, axoguard nerve connector, axoguard nerve protector, and more.

While we acknowledge the potential of AXGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.